SB465

Passed Senate

classifying xylazine as a schedule III controlled drug.

Senate Judiciary 2026 Session

Status

Introduced

Senate Committee

Senate Vote

House

House Vote

Governor

No upcoming hearing scheduled.

Support 15

Oppose 3

18 total submissions

Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5

Senate

February 24, 2026

Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5

Senate

February 24, 2026

Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8

Senate

February 20, 2026

Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A

Senate

February 05, 2026

Introduced 01/07/2026 and Referred to Judiciary; SJ 1

Senate

November 21, 2025

Loading bill text...